Lung Cancer Awareness Month: Our Commitment to Improving Lung Surgery

Hero Image

Lung cancer is one of the deadliest cancers in the world. When diagnosed early, thoracic surgery is often a preferred treatment method. We’re committed to improving thoracic surgery, with a focus on three key areas: improving surgical outcomes through a comprehensive, evidence-backed product portfolio; driving professional development through world-class education and innovative digital technologies; and advancing thoracic surgery through purposeful innovation and strategic acquisitions.

Creating evidence-backed products through research.

Our commitment to improving outcomes serves as the backbone of our innovation and the common goal between Ethicon and our customers. We strive to reduce complications by designing tissue specific products, validating the safety and efficacy with evidence, deeply understanding the effects on tissue, and using those insights to guide future innovation. By harnessing the power of big data, we are gaining insights into the impact of our devices on important thoracic outcomes, including real-world evidence demonstrating reduced bleeding complications with our powered staplers. Additionally, we have developed our Physiologic Lung Model, a first of its kind model that closely mimics natural breathing. With this model, we are striving towards better understanding about air leaks, a frequently occurring complication after thoracic surgery – data to improve our staplers.

Comprehensive device training for improved technique and better surgical outcomes.

For 130 years, the Johnson & Johnson Institute has driven professional development for healthcare professionals. Our online learning platform—with targeted offerings for residents, fellows and attending surgeons—aims to shape the future of surgical education. We offer over 40 thoracic surgical videos and courses such as VATS and Uniportal Lobectomy and Segmentectomy, and Minimally Invasive Esophagectomy. We’re investing in technology to provide advanced professional education courses for a safe and effective use of our devices, such as virtual reality, new simulators and online learning. These efforts make ongoing products education more accessible and give surgeons the tools and resources they need to continue improving technique and ultimately, surgical outcomes.

Strategic innovations and portfolio expansions to improve lung cancer care.

The Lung Cancer Initiative (LCI) at Johnson & Johnson is a patient-centric R&D team dedicated to leveraging the resources of J&J. An exciting step toward this goal was the acquisition of Auris Health, robotically assisted bronchoscopy, and the Monarch Platform. This robotic technology, which helps physicians diagnose hard-to-reach lung lesions, minimally invasive, will allow us to address key steps in the lung disease journey. “As a representative of Medical Devices in the Lung Cancer Initiative, our vision is to develop solutions that will prevent, intercept and cure lung cancer, enabling a future where we help to minimize impact of this devastating disease,” said Tom O’Brien, WW President EndoMechanical, Ethicon. “The establishment of the Lung Cancer Initiative represents our commitment to bringing together a vast community of talent and expertise to work collectively to realize the full potential of lung cancer science. Together, we are striving to rewriting the story of lung disease.”

This Lung Cancer Awareness Month, we’re refocusing on our commitment to best support the surgeons who work to treat this deadly disease. Together, these efforts advance our commitment to shaping the future of lung surgery. Join us in the fight against lung cancer.